Since the TPO receptor (TPOR), myeloproliferative leukemia virus protooncogene (cMpl-r), is the primary target to treat thrombocytopenia, thrombopoietin mimetics were developed that have no sequence homology to endogenous TPO (e.g. Romiplostim, Eltrombopag, and JNJ‐26366821). The gene discussed is TPO; the disease is Thrombocytopenia.